Greatest International Antiinfective Trial With Avelox (GIANT)

Bayer

Status: Completed

Conditions: Bronchitis, Chronic; Bronchial Diseases

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00932802

12218 (Other Identifier)

12227 (Other Identifier)

12231 (Other Identifier)

12228 (Other Identifier)

12229

12223 (Other Identifier)

12215 (Other Identifier)

12222 (Other Identifier)

12212

12214

12220

AX0401 (Other Identifier)

12234 (Other Identifier)

12217 (Other Identifier)

12206 (Other Identifier)

12221 (Other Identifier)

12213

11828 (Other Identifier)

12224 (Other Identifier)

12232

12211 (Other Identifier)

12216 (Other Identifier)

12225 (Other Identifier)

12233 (Other Identifier)

12226 (Other Identifier)

12219 (Other Identifier)

12235 (Other Identifier)

12230 (Other Identifier)

Details and patient eligibility

About

The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit (baseline) and at least one short-term follow-up visit (=initial treatment period).Optionally, long-term follow-ups (6 and 12 months) were documented, and a patient questionnaire was filled in.

Enrollment: 50,000 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Outpatients with diagnosis of AECB and decision taken by the investigator to prescribe moxifloxacin

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information

Trial design

50,000 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)